-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on August 27 Recently, Hengrui Medicine has entered the administrative examination and approval stage with the imitation of the 3 types of poppy iodized oil injection, which is expected to be approved and deemed to have been reviewed
.
Opium poppy lipiodol injection is an iodinated contrast agent.
In 2020, the terminal sales of public medical institutions in China will exceed 100 million yuan, and Hengrui Medicine will sell this product exclusively
.
.
Opium poppy lipiodol injection is an iodinated contrast agent.
In 2020, the terminal sales of public medical institutions in China will exceed 100 million yuan, and Hengrui Medicine will sell this product exclusively
.
Lipiodol injection of iodinated poppy acetate poppyseed oil, an iodinated contrast agent, suitable for lymphography, hepatocellular contrast, hysterosalpingography like
.
Lipiodol injection was first approved for marketing in the United States in March 1954, and it has been listed in many countries around the world
.
French Gabor's iodized oil injection was approved for import in China in August 2001
.
.
Lipiodol injection was first approved for marketing in the United States in March 1954, and it has been listed in many countries around the world
.
French Gabor's iodized oil injection was approved for import in China in August 2001
.
Hengrui Medicine poppies B iodized oil injection consistent with the innovator product the main active ingredient, as iodized poppyseed oil fatty acid ethyl ester, acetic currently poppy injection of iodized oil domestic production enterprises only Hengrui Medicine
.
.
According to data from Minai.
com, in 2020, the sales of terminal poppy dilipodol injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 100 million yuan, an increase of 28.
51% year-on-year
.
com, in 2020, the sales of terminal poppy dilipodol injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 100 million yuan, an increase of 28.
51% year-on-year
.
Sales of poppy iodized oil at terminal in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Hengrui Medicine's opium poppy lipiodol injection (10ml: 4.
8g) was approved for listing in September 2016.
The company did not submit an application for consistency evaluation of the product, but chose to submit a listing application under the new registration classification.
The product is currently registered The processing status has changed to "under review", and if it is successfully approved, it will be deemed as over-evaluated
.
8g) was approved for listing in September 2016.
The company did not submit an application for consistency evaluation of the product, but chose to submit a listing application under the new registration classification.
The product is currently registered The processing status has changed to "under review", and if it is successfully approved, it will be deemed as over-evaluated
.
Data source: Mi Neiwang database, NMPA
Medical Network News on August 27 Recently, Hengrui Medicine has entered the administrative examination and approval stage with the imitation of the 3 types of poppy iodized oil injection, which is expected to be approved and deemed to have been reviewed
.
Opium poppy lipiodol injection is an iodinated contrast agent.
In 2020, the terminal sales of public medical institutions in China will exceed 100 million yuan, and Hengrui Medicine will sell this product exclusively
.
.
Opium poppy lipiodol injection is an iodinated contrast agent.
In 2020, the terminal sales of public medical institutions in China will exceed 100 million yuan, and Hengrui Medicine will sell this product exclusively
.
Lipiodol injection of iodinated poppy acetate poppyseed oil, an iodinated contrast agent, suitable for lymphography, hepatocellular contrast, hysterosalpingography like
.
Lipiodol injection was first approved for marketing in the United States in March 1954, and it has been listed in many countries around the world
.
French Gabor's iodized oil injection was approved for import in China in August 2001
.
.
Lipiodol injection was first approved for marketing in the United States in March 1954, and it has been listed in many countries around the world
.
French Gabor's iodized oil injection was approved for import in China in August 2001
.
Hengrui Medicine poppies B iodized oil injection consistent with the innovator product the main active ingredient, as iodized poppyseed oil fatty acid ethyl ester, acetic currently poppy injection of iodized oil domestic production enterprises only Hengrui Medicine
.
.
According to data from Minai.
com, in 2020, the sales of terminal poppy dilipodol injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 100 million yuan, an increase of 28.
51% year-on-year
.
com, in 2020, the sales of terminal poppy dilipodol injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 100 million yuan, an increase of 28.
51% year-on-year
.
Sales of poppy iodized oil at terminal in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Hengrui Medicine's opium poppy lipiodol injection (10ml: 4.
8g) was approved for listing in September 2016.
The company did not submit an application for consistency evaluation of the product, but chose to submit a listing application under the new registration classification.
The product is currently registered The processing status has changed to "under review", and if it is successfully approved, it will be deemed as over-evaluated
.
8g) was approved for listing in September 2016.
The company did not submit an application for consistency evaluation of the product, but chose to submit a listing application under the new registration classification.
The product is currently registered The processing status has changed to "under review", and if it is successfully approved, it will be deemed as over-evaluated
.
Data source: Mi Neiwang database, NMPA
Medical Network News on August 27 Recently, Hengrui Medicine has entered the administrative examination and approval stage with the imitation of the 3 types of poppy iodized oil injection, which is expected to be approved and deemed to have been reviewed
.
Opium poppy lipiodol injection is an iodinated contrast agent.
In 2020, the terminal sales of public medical institutions in China will exceed 100 million yuan, and Hengrui Medicine will sell this product exclusively
.
.
Opium poppy lipiodol injection is an iodinated contrast agent.
In 2020, the terminal sales of public medical institutions in China will exceed 100 million yuan, and Hengrui Medicine will sell this product exclusively
.
Lipiodol injection of iodinated poppy acetate poppyseed oil, an iodinated contrast agent, suitable for lymphography, hepatocellular contrast, hysterosalpingography like
.
Lipiodol injection was first approved for marketing in the United States in March 1954, and it has been listed in many countries around the world
.
French Gabor's iodized oil injection was approved for import in China in August 2001
.
.
Lipiodol injection was first approved for marketing in the United States in March 1954, and it has been listed in many countries around the world
.
French Gabor's iodized oil injection was approved for import in China in August 2001
.
Hengrui Medicine poppies B iodized oil injection consistent with the innovator product the main active ingredient, as iodized poppyseed oil fatty acid ethyl ester, acetic currently poppy injection of iodized oil domestic production enterprises only Hengrui Medicine
.
Pharmaceutical Pharmaceutical Pharmaceutical Enterprise Enterprise Enterprise.
According to data from Minai.
com, in 2020, the sales of terminal poppy dilipodol injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 100 million yuan, an increase of 28.
51% year-on-year
.
Hospital hospital hospitalcom, in 2020, the sales of terminal poppy dilipodol injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 100 million yuan, an increase of 28.
51% year-on-year
.
Sales of poppy iodized oil at terminal in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Hengrui Medicine's opium poppy lipiodol injection (10ml: 4.
8g) was approved for listing in September 2016.
The company did not submit an application for consistency evaluation of the product, but chose to submit a listing application under the new registration classification.
The product is currently registered The processing status has changed to "under review", and if it is successfully approved, it will be deemed as over-evaluated
.
8g) was approved for listing in September 2016.
The company did not submit an application for consistency evaluation of the product, but chose to submit a listing application under the new registration classification.
The product is currently registered The processing status has changed to "under review", and if it is successfully approved, it will be deemed as over-evaluated
.
Data source: Mi Neiwang database, NMPA
